CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed”) and PharmaChoice today signed a letter of intent to collaborate on pharmacist education and the distribution, sale and marketing of medical cannabis products.

This industry-leading collaboration will see CanniMed responsible for producing and delivering accredited pharmacy education programs to PharmaChoice pharmacists and pharmacy technicians across Canada. In addition, CanniMed and PharmaChoice intend to enter a definitive agreement for distribution of medical cannabis through PharmaChoice pharmacists in Canada upon completion of the first provincial legislation change that allows such distribution.

The University of Waterloo has inked a sponsored research agreement with Algae Dynamics Corp. to perform fundamental research on cannabis oil and its constituents, with an eye toward developing treatment of cancers of the colorectum, pancreas, breast and prostate.

This announcement follows the Algae Dynamics previously announced new strategic initiative to explore the extraction of oils from other botanicals in addition to algae, most notably cannabis, and to seek product development and formulation opportunities that combine the benefits of algae and cannabis oils.

Four U.S. states have legalized recreational cannabis, and another four will follow after ballot victories last November.

Organigram Holdings Inc. (TSX VENTURE:OGI) (OTCQB:OGRMF) (the "Company") has appointed a medical marijuana, pharmaceutical, and biotechnology industry veteran as its new chief executive officer.

Greg Engel will assume his new role effective March 13, 2017. Mr. Engel succeeds Organigram's current CEO Denis Arsenault who is stepping up to the newly created executive chairman's position. Engel will also join the Board of Directors of Organigram, replacing Larry Rogers, who steps down from the Board, but remains an important part of the Senior Management team.

Horizons has filed a preliminary prospectus for a new ETF to help investors get into cannabis stocks.

The Horizons Medical Marijuana Life Sciences ETF, which will trade under the ticker HMMJ on the Toronto Stock Exchange.

Marijuana stocks like Canopy Growth (WEED.TO) have piqued the interest of Canadian investors since moving over from the Venture exchange in 2016.

But Jacob Capital Management Head of Research Khurram Malik, told BNN Monday that proposed cannabis ETFs might not be the pure play investors might be looking for in the marijuana space.

Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to new research.

Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to new research by the University of British Columbia and University of Victoria. "This study is one of the first to track medical cannabis use under the new system of licensed producers, meaning that all participants had physician authorization to access cannabis in addition to their prescription medicines," says UBC Assoc. Prof. Zach Walsh, co-author of the study.

Organigram Holdings Inc (CVE:OGI) (OTCMKTS:OGRMF) has held up nicely in spite of a a product recall and profit taking in the cannabis sector. The product recall was initially bad news for the company, but the company handled it in the same way that Johnson & Johnson handled the Tylenol recall in the 1980s. Organigram’s aggressive response strengthened the company’s brand in the eyes of its customers and this bodes well for shareholders. Taking a closer look, it’s easy to see why Organigram remains a top cannabis pick for 2017 and beyond.

Longtime landlord Darryl Spencer was left scrambling for insurance after discovering a tenant was growing dozens of medical marijuana plants inside and outside his rental house.

When the landlord told his insurance company about the perfectly legal grow-op, his coverage was cancelled, leaving him with no insurance, few rights and a big cleanup bill.

The downstairs tenant in Spencer's Kamloops, B.C., rental property got a medical marijuana licence that allowed him to legally grow as many as 60 plants without his landlord's permission or knowledge.

A call from a concerned neighbour prompted Spencer, who is also a retired fire inspector, to check out the home he's rented out to different tenants for a decade.

Shares of Canadian and U.S. marijuana producers fell Friday after the Trump administration suggested a crackdown on recreational marijuana may be in the works.

Most of Canada’s publicly traded pot growers ended Friday lower after White House Press Secretary Sean Spicer predicted the Justice Department will be looking more closely at the issue.

“I do believe that you’ll see greater enforcement of it,” Spicer said at a White House briefing.

A Canadian medical marijuana company has taken matters into its own hands amid a tainted cannabis scare that has left Health Canada struggling to reassure patients the products sold by federally licensed producers can be trusted.

CanniMed Therapeutics Inc., based in Saskatoon, has taken the unusual step of commissioning independent lab tests on some of its products and making the data public to show consumers that its medicine contains no banned pesticides.